Centre Hospitalier De La Cote Basque
Verified site
Bayonne, France
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on patients with high‑grade upper tract urothelial carcinoma, a cancer that starts in the lining of the kidney’s collecting system or the ureter. The treatment being tested combines two chemotherapy drugs, gemcitabine and cisplatin, which are given through a vein to kill rapidly growing cells, with an immunotherapy drug called avelumab that helps the immune system recognize and attack cancer cells. Some participants will receive only the chemotherapy drugs, while others will receive the chemotherapy together with the immunotherapy.
The main aim of the research is to see whether adding immunotherapy to standard chemotherapy improves outcomes before surgery. In the study, patients receive a series of intravenous infusions of the assigned medicines over several weeks, followed by the planned surgical removal of the tumor. This approach, known as neoadjuvant treatment, is intended to shrink the tumor and make the operation safer.
After treatment and surgery, participants are followed for several years to track how long they remain free of disease, measured as event-free survival, which means the time without cancer returning, spreading, or causing death. Doctors also examine the removed tissue to determine if a pathologic complete response was achieved, meaning no living cancer cells are found. Throughout the study, safety is monitored by recording any side effects and by regular health questionnaires.
The trial runs in 10 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
7 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Bayonne, France
Vandoeuvre Les Nancy, France
Creteil, France
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a chemotherapy drug that is given through a vein. In this study it is part of the standard platinum‑based chemotherapy regimen used before surgery. The medicine works by stopping cancer cells from growing and dividing, helping to shrink the tumor before it is removed.
is another chemotherapy drug that is also given intravenously. It belongs to the platinum‑based class of medicines and is paired with gemcitabine in the trial’s chemotherapy arm. Cisplatin damages the DNA of cancer cells, which slows or stops their growth, contributing to tumor reduction before surgery.
is an immunotherapy medicine that is given by IV infusion. It is a type of drug called a checkpoint inhibitor, which helps the body’s immune system recognize and attack cancer cells. In this trial, avelumab is added to the gemcitabine‑cisplatin chemotherapy to see if the combination works better than chemotherapy alone in shrinking the tumor before surgery.
Given by intravenous infusion, gemcitabine is an approved chemotherapy drug used for many solid tumors such as bladder, lung and pancreatic cancer. It works by mimicking a building block of DNA, so when cancer cells try to copy their DNA, gemcitabine blocks the process and stops their growth. It belongs to the antimetabolite class of chemotherapy agents and is listed in current medical guidelines and literature as a standard treatment option.
Administered as an intravenous bolus followed by a short infusion, avelumab is a licensed immunotherapy used for cancers like Merkel cell carcinoma and urothelial carcinoma. It is a monoclonal antibody that blocks the protein PD‑L1, helping the body’s immune cells recognise and destroy cancer cells. This drug is classified as a checkpoint inhibitor and is widely described in recent clinical studies as an effective immune‑based therapy.
Delivered through intravenous infusion, cisplatin is a long‑standing chemotherapy drug approved for a wide range of cancers, including bladder and lung cancers. It attaches to DNA and creates strong links that prevent the DNA strands from separating, which stops cancer cells from dividing and leads to their death. Cisplatin belongs to the platinum‑based chemotherapy class and remains a cornerstone of cancer treatment in current medical practice.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.